Alzheimer's disease (AD) affects an estimated 44 million individuals worldwide, yet no
therapeutic intervention is available to stop the progression of the dementia …

Background Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab
and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal …

Objective Vedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of
ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the …

Importance Despite established genetic and pathophysiologic links between inflammatory
bowel disease (IBD) and Parkinson disease (PD), clinical data supporting this association …

Simple Summary Inflammation has been acknowledged as one of the causes of increased
cancer risk. Among the pro-inflammatory mediators, tumor necrosis factor alpha (TNFα) has …

Background: Mounting evidence demonstrates enhanced systemic levels of inflammatory
mediators in depression, indicating that inflammation may play a role in the etiology and …

Introduction: Biological drugs are therapies designed to target a specific molecule of the
immune system that have been linked with the development of autoimmune diseases. Areas …

Objective To provide a systematic review of the literature regarding the efficacy of anti‐
inflammatory drugs in three major mental disorders [major depressive disorder (MDD) …

Anti-tumour necrosis factor (TNF)-α agents have been increasingly used to treat patients
affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory …

Inflammatory bowel diseases (IBD) are chronic inflammatory conditions affecting the
digestive system, comprising two main distinctive entities, ulcerative colitis (UC) and Crohn's …